



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



DUSP22-IRF4 Rearrangement

Alternative Name

IRF4 Rearrangement

Methodology

FISH

Test Description

Probes: DUSP22-IRF4 gene region at 6p25.3

Disease(s): Anaplastic Large Cell Lymphoma (ALCL), large B-cell lymphoma

Clinical Significance

Gene rearrangements involving the DUSP22-IRF4 gene region have been reported in CD30-positive, ALK-negative anaplastic large cell lymphoma and are associated with a favorable clinical outcome. Rearrangement has been reported in a subset of patients with lymphomatoid papulosis (LyP). Testing may identify large B-cell lymphoma with IRF4 gene rearrangement, also with favorable outcome.

DUSP22 and IRF4 are adjacent genes at 6p25.3; this test does not identify the gene rearrangement partner. MUM1 is the protein expressed by the IRF4 gene. FISH for IRF4 rearrangements has greater specificity for cutaneous ALCL than MUM1 IHC.

Specimen Requirements

- **Bone Marrow Aspirate:** N/A
- **Peripheral Blood:** N/A
- **Fresh, Unfixed Tissue:** N/A
- **Fluids:** N/A
- **Paraffin Block:** H&E slide (required) plus paraffin block. Circle H&E for tech-only.
- **Cut Slides:** H&E slide (required) plus 2 unstained slides cut at 4 microns. Circle H&E for tech-only.

Storage & Transportation

Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

88374x1 automated or 88377x1 manual

New York Approved

Yes

Level of Service

Global, Technical

Turnaround Time

3-5 days

References

1. Pedersen MB, Hamilton Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*. 2017; 130:554-557.
2. Parrilla Castellar ER, Jaffe ES, Said JS, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*. 2014; 124:1473-1480.
3. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. *Mod Pathol*. 2011; 24:596-605.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 042224